PF-4605412

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePF-4605412

Drug Alias NamePF-04605412

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionImmunostimulantsIntegrin alpha-5/beta-1 antagonists

TargetsIntegrin alpha-5/beta-1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeN/A